Heartsciences INC Form 4 insider transactions

HeartSciences Inc. reports the grant of 25,000 restricted stock units to Chief Financial Officer Danielle Watson, contingent on a merger closing and continued employment.

Andrew Simpson, Director and CEO of HeartSciences Inc., received a grant of 425,000 shares of common stock as a retention bonus tied to a merger agreement.

HeartSciences Inc. director David R. Wells was granted 15,000 Restricted Stock Units, subject to shareholder approval and performance-based vesting conditions.

HeartSciences Inc. Director Bruce Bent received a grant of 15,000 Restricted Stock Units, subject to vesting conditions including shareholder approval, time-based milestones, and performance targets.

HeartSciences Inc. Chief Operating Officer Mark T. Hilz was granted 45,000 Restricted Stock Units, vesting over three years with performance and change of control accelerators.

HeartSciences Inc. Director Brian Szymczak was granted 15,000 Restricted Stock Units, subject to specific vesting conditions including shareholder approval and performance targets.

HeartSciences Inc. Chief Financial Officer Danielle Watson received a grant of 15,000 Restricted Stock Units, subject to specific vesting conditions including shareholder approval and performance targets.

HeartSciences Inc. CEO Andrew Simpson was granted 70,000 shares of common stock under the company's 2023 Equity Incentive Plan, increasing his beneficial ownership to 74,382 shares.

HeartSciences Inc.'s COO and Director, Mark T. Hilz, sold 4,416 shares of common stock for a weighted average price of $3.5374 per share, executed under a Rule 10b5-1 trading plan.

HeartSciences Inc. Director Bruce Bent was granted 25,000 stock options with an exercise price of $4.37, vesting over time and expiring in 2035.

HeartSciences Inc. Director Brian Szymczak was granted 25,000 stock options with an exercise price of $4.37, vesting over time and expiring in 2035.

HeartSciences Inc. has granted its Chairman, President, and CEO, Andrew Simpson, 275,000 stock options and 68,750 Restricted Stock Units, with vesting largely contingent on future FDA regulatory clearance of its MyoVista wavECG device or AI-ECG algorithm.

HeartSciences Inc. Director David R. Wells was granted 25,000 stock options with an exercise price of $4.37, vesting over time, as part of the company's 2023 Equity Incentive Plan.

HeartSciences Inc. has granted its Chief Operating Officer and Director, Mark T. Hilz, 225,000 stock options and 56,250 restricted stock units, with vesting tied to regulatory milestones and continued employment.

HeartSciences Inc. Chief Financial Officer Danielle Watson was granted 25,000 stock options with an exercise price of $4.37, vesting over three years or upon key regulatory milestones.

Director Bruce Bent acquired 6,000 employee stock options in HeartSciences Inc. on January 16, 2025, according to a Form 4 filing.

HeartSciences Inc. Chief Operating Officer Mark T. Hilz was granted 45,000 stock options, vesting over time and upon FDA regulatory clearance.

HeartSciences Inc. director David R. Wells was granted 6,000 stock options with a $3.33 exercise price, vesting over three years.

HeartSciences' Chief Financial Officer, Danielle Watson, was granted 9,000 stock options with a vesting schedule tied to continued employment and regulatory approval of the company's MyoVista device.

HeartSciences Inc. director Brian Szymczak was granted 6,000 stock options, vesting over three years, as part of the company's 2023 Equity Incentive Plan.

Andrew Simpson, Chairman, President, and CEO of HeartSciences Inc., reports the grant of employee stock options.

Andrew Simpson, a director at Heart Test Laboratories, acquired 17 shares of common stock from the Simpson Family Benefit Trust on August 12, 2024.